Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 31, 2011, Pages 12943-12948

  Zhu, Feng ^a,b   Qin, Chu ^b   Tao, Lin ^b   Liu, Xin ^b   Shi, Zhe ^b   Ma, Xiaohua ^b   Jia, Jia ^b   Tan, Ying ^a   Cui, Cheng ^a   Lin, Jinshun ^a   Tan, Chunyan ^a   Jiang, Yuyang ^a,c   Chen, Yuzong ^a,b  

^a TSINGHUA UNIVERSITY   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c Graduate School for Integrative Sciences and Engineering ^*  (China)

Author keywords

Biodiversity; Drug prolific species; Herb; Phylogenetic tree

Indexed keywords

ANTIINFECTIVE AGENT; NATURAL PRODUCT;

ARTICLE; BACTERIUM; BIODIVERSITY; MEDICINAL PLANT; METAZOON; NONHUMAN; PHYLOGENETIC TREE; PRIORITY JOURNAL; PRODUCTIVITY; PSEUDONOCARDIACEAE; STREPTOMYCETACEAE; VIRIDIPLANTAE;

EID: 79961223344     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1107336108     Document Type: Article

References (59)

1. Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70:461-477.
2. Butler MS (2008) Natural products to drugs: Natural product-derived compounds in clinical trials. Nat Prod Rep 25:475-516.
3. Paul SM, et al. (2010) How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat Rev Drug Discov 9:203-214.
4. Li JW, Vederas JC (2009) Drug discovery and natural products: End of an era or an endless frontier? Science 325:161-165.
5. Butchart SH, et al. (2010) Global biodiversity: Indicators of recent declines. Science 328:1164-1168.
6. Vistoli G, Pedretti A, Testa B (2008) Assessing drug-likeness - what are we missing? Drug Discov Today 13:285-294.
7. Bemis GW, Murcko MA (1996) The properties of known drugs. 1. Molecular frameworks. J Med Chem 39:2887-2893.
8. Wang J, Hou T (2010) Drug and drug candidate building block analysis. J Chem Inf Model 50:55-67.
9. Duarte CD, Barreiro EJ, Fraga CA (2007) Privileged structures: A useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem 7:1108-1119.
10. Koch MA, et al. (2005) Charting biologically relevant chemical space: A structural classification of natural products (SCONP). Proc Natl Acad Sci USA 102:17272-17277.
11. Kong DX, Jiang YY, Zhang HY (2010) Marine natural products as sources of novel scaffolds: Achievement and concern. Drug Discov Today 15:884-886.
12. Fischbach MA, Clardy J (2007) One pathway, many products. Nat Chem Biol 3:353-355.
13. Beghyn T, Deprez-Poulain R, Willand N, Folleas B, Deprez B (2008) Natural compounds: Leads or ideas? Bioinspired molecules for drug discovery. Chem Biol Drug Des 72:3-15.
14. Nett M, Ikeda H, Moore BS (2009) Genomic basis for natural product biosynthetic diversity in the actinomycetes. Nat Prod Rep 26:1362-1384.
15. Fenical W, Jensen PR (2006) Developing a new resource for drug discovery: Marine actinomycete bacteria. Nat Chem Biol 2:666-673.
16. Tulp M, Bohlin L (2002) Functional versus chemical diversity: Is biodiversity important for drug discovery? Trends Pharmacol Sci 23:225-231.
17. Bérdy J (2005) Bioactive microbial metabolites. J Antibiot (Tokyo) 58:1-26.
18. Tulp M, Bohlin L (2005) Rediscovery of known natural compounds: Nuisance or goldmine? Trends Pharmacol Sci 26:175-177.
19. Saklani A, Kutty SK (2008) Plant-derived compounds in clinical trials. Drug Discov Today 13:161-171.
20. Baell JB, Holloway GA (2010) New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 53:2719-2740.
21. Ekins S, Honeycutt JD, Metz JT (2010) Evolving molecules using multi-objective optimization: Applying to ADME/Tox. Drug Discov Today 15:451-460.
22. Wang J (2009) Comprehensive assessment of ADMET risks in drug discovery. Curr Pharm Des 15:2195-2219.
23. Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5:993-996.
24. Zhu F, et al. (2010) Update of TTD: Therapeutic Target Database. Nucleic Acids Res 38(Database issue):D787-D791.
25. Gu L, et al. (2009) Metamorphic enzyme assembly in polyketide diversification. Nature 459:731-735.
26. Gontang EA, Gaudêncio SP, Fenical W, Jensen PR (2010) Sequence-based analysis of secondary-metabolite biosynthesis in marine actinobacteria. Appl Environ Microbiol 76:2487-2499.
27. Perić-Concha N, Long PF (2003) Mining the microbial metabolome: A new frontier for natural product lead discovery. Drug Discov Today 8:1078-1084.
28. Walsh CT, Fischbach MA (2010) Natural products version 2.0: Connecting genes to molecules. J Am Chem Soc 132:2469-2493.
29. Ososki AL, Kennelly EJ (2003) Phytoestrogens: A review of the present state of research. Phytother Res 17:845-869.
30. Vicente F, et al. (2009) Distribution of the antifungal agents sordarins across filamentous fungi. Mycol Res 113:754-770.
31. Simmons TL, Andrianasolo E, McPhail K, Flatt P, Gerwick WH (2005) Marine natural products as anticancer drugs. Mol Cancer Ther 4:333-342.
32. Pfisterer PH, Wolber G, Efferth T, Rollinger JM, Stuppner H (2010) Natural products in structure-assisted design of molecular cancer therapeutics. Curr Pharm Des 16:1718-1741.
33. Steinmetz KL, Spack EG (2009) The basics of preclinical drug development for neurodegenerative disease indications. BMC Neurol 9(Suppl 1):S2 1-13.
34. Saladin PM, Zhang BD, Reichert JM (2009) Current trends in the clinical development of peptide therapeutics. IDrugs 12:779-784.
35. Woodcock J, et al. (2007) The FDA's assessment of follow-on protein products: A historical perspective. Nat Rev Drug Discov 6:437-442.
36. Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9:767-774.
37. Melnikova I (2007) RNA-based therapies. Nat Rev Drug Discov 6:863-864.
38. Bergmann S, et al. (2007) Genomics-driven discovery of PKS-NRPS hybrid metabolites from Aspergillus nidulans. Nat Chem Biol 3:213-217.
39. Lautru S, Deeth RJ, Bailey LM, Challis GL (2005) Discovery of a new peptide natural product by Streptomyces coelicolor genome mining. Nat Chem Biol 1:265-269.
40. Chiang YM, Chang SL, Oakley BR, Wang CC (2011) Recent advances in awakening silent biosynthetic gene clusters and linking orphan clusters to natural products in microorganisms. Curr Opin Chem Biol 15:137-143.
41. Wenzel SC, Müller R (2005) Formation of novel secondary metabolites by bacterial multimodular assembly lines: Deviations from textbook biosynthetic logic. Curr Opin Chem Biol 9:447-458.
42. Wilkinson B, Micklefield J (2007) Mining and engineering natural-product biosynthetic pathways. Nat Chem Biol 3:379-386.
43. Pullen CB, et al. (2003) Occurrence and non-detectability of maytansinoids in individual plants of the genera Maytenus and Putterlickia. Phytochemistry 62:377-387.
44. Schroeckh V, et al. (2009) Intimate bacterial-fungal interaction triggers biosynthesis of archetypal polyketides in Aspergillus nidulans. Proc Natl Acad Sci USA 106:14558-14563.
45. Baltz RH (2008) Renaissance in antibacterial discovery from actinomycetes. Curr Opin Pharmacol 8:557-563.
46. Marris E (2006) Marine natural products: Drugs from the deep. Nature 443:904-905.
47. Mayer AM, et al. (2010) The odyssey of marine pharmaceuticals: A current pipeline perspective. Trends Pharmacol Sci 31:255-265.
48. Singh S (2007) From exotic spice to modern drug? Cell 130:765-768.
49. Saleem M, et al. (2007) Marine natural products of fungal origin. Nat Prod Rep 24: 1142-1152.
50. Cheng SY, et al. (2010) Antiviral and anti-inflammatory metabolites from the soft coral Sinularia capillosa. J Nat Prod 73:771-775.
51. Mortari MR, Cunha AO, Ferreira LB, dos Santos WF (2007) Neurotoxins from invertebrates as anticonvulsants: From basic research to therapeutic application. Pharmacol Ther 114:171-183.
52. Zheng CJ, et al. (2006) Therapeutic targets: Progress of their exploration and investigation of their characteristics. Pharmacol Rev 58:259-279.
53. Bilanges B, Torbett N, Vanhaesebroeck B (2008) Killing two kinase families with one stone. Nat Chem Biol 4:648-649.
54. Cragg GM, Newman DJ (2005) Plants as a source of anti-cancer agents. J Ethnopharmacol 100:72-79.
55. Harvey A (2000) Strategies for discovering drugs from previously unexplored natural products. Drug Discov Today 5:294-300.
56. Scherlach K, Hertweck C (2009) Triggering cryptic natural product biosynthesis in microorganisms. Org Biomol Chem 7:1753-1760.
57. Chiang YM, Lee KH, Sanchez JF, Keller NP, Wang CC (2009) Unlocking fungal cryptic natural products. Nat Prod Commun 4:1505-1510.
58. Sayers EW, et al. (2009) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 37(Database issue):D5-D15.
59. Ciccarelli FD, et al. (2006) Toward automatic reconstruction of a highly resolved tree of life. Science 311:1283-1287.